Contains monographs for drug substances, dosage forms, and general chapters. NF 34: Contains monographs for excipients.
: Updated practices for compounding pharmacies aimed to reduce contamination risks through stricter aseptic techniques and environmental monitoring.
– Toxicological safety assessment of extractables and leachables (planned at the time of USP 39)
For unique litigation, patent disputes, or legacy product registrations requiring a certified copy of a specific 2016 monograph, the USP can provide official, authenticated excerpts upon request.
: Protocols for sterility tests and microbial limits were refined to provide more stringent steps for sample collection and interpretation. Accessing the USP 39 PDF usp 39 pdf
Historically, the USP-NF was distributed as a massive, multi-volume print book or via local CD-ROM installations. The PDF version became a popular intermediary tool because it offered: Instant text searchability for rapid troubleshooting.
One of the most frequently searched terms in this domain is This refers to the 39th edition of the United States Pharmacopeia, which was officially in effect from May 1, 2016, through April 30, 2017. While newer editions have since been released (USP 40, USP 41, USP 42, and the current USP–NF 2024), USP 39 remains a highly referenced benchmark for compliance, legacy product documentation, and historical regulatory research.
Instead of hunting for historical PDF copies, users can view past versions of a monograph (including the USP 39 text) directly within the modern interface using the built-in history tool.
Outlining the gel-clot, turbidimetric, and chromogenic techniques for Limulus Amebocyte Lysate (LAL) testing in parenterals. Contains monographs for drug substances, dosage forms, and
USP 39–NF 34 (2016) established mandatory quality standards for drug substances and excipients while introducing structural, formatting, and technical updates to improve compliance and align with global regulatory expectations. Key updates in this edition included new standards for handling hazardous drugs, revised elemental impurity guidelines, and the restructuring of chapters related to plastic packaging. Detailed information on the 2016 publication announcements can be found at USP 39–NF 34 General Chapter . Commentary USP 39–NF 34
Standard Operating Procedure (SOP) alignment and audit preparation. (Dissolution), (Method Validation)
While the industry constantly progresses to newer annual revisions, understanding the architecture of the USP 39, knowing how to legally navigate its PDF version, and mastering its core general chapters is essential for maintaining global compliance standards. Understanding the USP 39-NF 34 Framework
Each monograph typically includes sections on definition, identification, specific tests or assays, impurity limits, and packaging and storage requirements. The PDF version became a popular intermediary tool
: Chapter provides specific limits for the amount of elemental impurities (like lead, mercury, and arsenic) allowed in drug products.
Focuses specifically on excipients, binders, colorants, and other inactive ingredients critical to formulation development.
The General Notices and Requirements section (General Notices) presents the basic assumptions, definitions, and default conditions for the interpretation and application of the USP and NF. Requirements stated in the General Notices apply to all articles recognized in the USP and NF and to all general chapters unless specifically stated otherwise.
Specifically focuses on excipients (inactive ingredients) like binders, coatings, and stabilizers. Key Technical Chapters in USP 39
Some pharmaceutical products were approved based on USP 39 standards. Companies performing stability studies or retrospective analyses may need to refer to the exact standards that were official at the time of a drug’s approval.
